Hideto Kameda

35PUBLICATIONS
67CO-AUTHORS
Predictive and prognostic markersRheumatology and arthritisCancer therapy (excl. chemotherapy and radiation therapy)Molecular imaging (incl. electron microscopy and neutron diffraction)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Jun 26, 2026
Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial.

|May 12, 2026
Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

|Jan 29, 2026
Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|Jan 28, 2026
Ultrasound evaluation of finger joint cartilage damage progression in patients with rheumatoid arthritis.

Takehisa Ogura, Chihiro Imaizumi, Ayako Hirata

|Nov 05, 2025
Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.

Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka

|Sep 05, 2025
Targeting IL-6 Signaling: Safety and Effectiveness in Older Patients with Rheumatoid Arthritis.

Hideto Kameda, Reina Maezawa, Yasuto Minegishi

Pageof 6

Frequent Collaborators

11 joint publications

Yoshiya Tanaka

7 joint publications

Yuko Kaneko

6 joint publications

Tsutomu Takeuchi

5 joint publications

Kei Ikeda